Harry Jr. Thomasian Sells 100,000 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN) CFO Harry Jr. Thomasian sold 100,000 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $6.06, for a total value of $606,000.00. Following the completion of the sale, the chief financial officer owned 254,535 shares in the company, valued at $1,542,482.10. The trade was a 28.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harry Jr. Thomasian also recently made the following trade(s):

• On Wednesday, July 1st, Harry Jr. Thomasian sold 171,429 shares of Precigen stock. The shares were sold at an average price of $5.53, for a total value of $948,002.37.
• On Monday, June 29th, Harry Jr. Thomasian sold 28,571 shares of Precigen stock. The shares were sold at an average price of $5.78, for a total value of $165,140.38.
• On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total value of $182,614.24.

Precigen Trading Up 5.6%

Precigen stock opened at $6.27 on Friday. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62. Precigen, Inc. has a 12 month low of $1.63 and a 12 month high of $6.28. The stock’s 50 day simple moving average is $4.98 and its two-hundred day simple moving average is $4.41. The firm has a market cap of $2.24 billion, a PE ratio of -5.31 and a beta of 1.00.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $23.25 million for the quarter, compared to analysts’ expectations of $20.81 million. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. Analysts anticipate that Precigen, Inc. will post -0.02 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on PGEN shares. Wall Street Zen lowered shares of Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. HC Wainwright upped their price objective on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Citizens Jmp raised their target price on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. Finally, Citigroup restated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $12.50.

Institutional Trading of Precigen

Large investors have recently made changes to their positions in the company. Royal Bank of Canada lifted its holdings in Precigen by 102.6% in the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,426 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Precigen by 61.0% during the first quarter. The Manufacturers Life Insurance Company now owns 90,143 shares of the biotechnology company’s stock worth $349,000 after buying an additional 34,137 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Precigen during the first quarter worth $1,531,000. State of Wyoming acquired a new stake in shares of Precigen in the first quarter valued at about $27,000. Finally, Cetera Investment Advisers raised its position in shares of Precigen by 0.9% in the first quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock valued at $1,449,000 after buying an additional 3,250 shares during the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.